Ethics of off-label treatment

被引：2

|

作者：

Atkins, CD ^{[1
]}

机构：

[1] S Shore Hematol Oncol Associates, Rockville Ctr, NY 11570 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 1998年 / 16卷 / 04期

关键词：

D O I：

10.1200/JCO.1998.16.4.1637

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

收藏

页码：1637 / 1637

页数：1

相关论文

共 50 条

[41] Opinion - The 'off-label' use of medicines in the treatment of animals
Beechinor, JG
IRISH VETERINARY JOURNAL, 2004, 57 (07) : 396 - 396
[42] PembrolizumabNeutropenia following off-label treatment: case report
Reactions Weekly, 2021, 1851 (1) : 288 - 288
[43] Off-label use of an angiogenic in the treatment of retinopathy of prematurity
Lede, Roberto
ARCHIVOS ARGENTINOS DE PEDIATRIA, 2016, 114 (05): : E392 - E393
[44] RivoceranibHaemafecia following off-label treatment: case report
Reactions Weekly, 2018, 1721 (1) : 263 - 263
[45] Subtype-Specific Off-Label Treatment of Rosacea
Wienholtz, Nita
Ashina, Messoud
Thyssen, Jacob P.
Egeberg, Alexander
CASE REPORTS IN DERMATOLOGY, 2021, 13 (01): : 121 - 128
[46] AnakinraToxidermia follwing off-label treatment: case report
Reactions Weekly, 2019, 1751 (1) : 35 - 35
[47] BexaroteneTransaminitis following an off-label treatment: case report
Reactions Weekly, 2019, 1741 (1) : 59 - 59
[48] Apremilast for the off-label treatment of lichenoid and interface dermatoses
Ravichandran, Surya
Kheterpal, Meenal K.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (05) : 1489 - 1491
[49] VenetoclaxNeutropenia following off-label treatment: case report
Reactions Weekly, 2021, 1849 (1) : 412 - 412
[50] FavipiravirLack of efficacy and off-label treatment: case report
Reactions Weekly, 2023, 1981 (1) : 179 - 179

← 1 2 3 4 5 →